High affinity binding, effectively blocking the interaction between PD-1 receptors on T cells and their ligands (PD-L1 and PD-L2) on tumor cells, thus restoring T-cell activitySignificant clinical activity observed in specific patient populations. The gene discussed is PDCD1LG2; the disease is neoplasm.